BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33117438)

  • 1. High-dose Somatostatin Analogues for Progressive Neuroendocrine Tumours.
    Sharp AJ; Hayes AR; Grossman A
    Eur Endocrinol; 2020 Oct; 16(2):93-95. PubMed ID: 33117438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P
    Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide - A Review of its Use in Treating Neuroendocrine Tumours.
    Costa F; Gumz B
    Eur Endocrinol; 2014 Feb; 10(1):70-74. PubMed ID: 29872467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
    Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
    Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
    Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
    Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A; Bodoky G
    Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
    Colao A; Faggiano A; Pivonello R
    Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
    De Martino MC; Hofland LJ; Lamberts SW
    Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
    Hejna M; Schmidinger M; Raderer M
    Ann Oncol; 2002 May; 13(5):653-68. PubMed ID: 12075733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting formulations of somatostatin analogues.
    Anthony LB
    Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of somatostatin analogue therapy.
    Stewart PM; James RA
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):409-18. PubMed ID: 10909432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
    Uomo G; Germano D; Rabitti PG
    Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
    Modlin IM; Pavel M; Kidd M; Gustafsson BI
    Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.